| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $0 ) |
| | 2026 | 2025 | GENEVENTIV THERAPEUTICS, INC. | 150 FAYETTEVILLE ST | RALEIGH | NC | 27601-2958 | WAKE | USA | R44HL174236 | Development of a universal gene therapy for hemophilia A or B with or without inhibitors | 000 | 2 | NIH | 1/7/2026 | $0 |
|
| Issue Date FY: 2025 ( Subtotal = $1,312,038 ) |
| | 2025 | 2025 | GENEVENTIV THERAPEUTICS, INC. | 150 FAYETTEVILLE ST | RALEIGH | NC | 27601-2958 | WAKE | USA | R44HL174236 | Development of a universal gene therapy for hemophilia A or B with or without inhibitors | 001 | 2 | NIH | 5/6/2025 | $45,344 |
| | 2025 | 2025 | GENEVENTIV THERAPEUTICS, INC. | 150 FAYETTEVILLE ST | RALEIGH | NC | 27601-2958 | WAKE | USA | R44HL174236 | Development of a universal gene therapy for hemophilia A or B with or without inhibitors | 000 | 2 | NIH | 3/25/2025 | $1,266,694 |
|
| Issue Date FY: 2024 ( Subtotal = $1,230,198 ) |
| | 2024 | 2024 | GENEVENTIV THERAPEUTICS, INC. | 150 FAYETTEVILLE ST | RALEIGH | NC | 27601-2958 | WAKE | USA | R44HL174236 | Development of a universal gene therapy for hemophilia A or B with or without inhibitors | 000 | 1 | NIH | 4/10/2024 | $1,230,198 |
|
|
